Scopus
YÖKSİS DOI Eşleşti
SJR Q1
Adverse COVID-19 outcomes in immune deficiencies: Inequality exists between subclasses
Allergy European Journal of Allergy and Clinical Immunology · Ocak 2022
YÖKSİS Kayıtları
Adverse COVID-19 outcomes in immune deficiencies: Inequality exists between subclasses
Allergy · 2022 SCI
Prof. Dr. HASİBE ARTAÇ →
YÖKSİS Kayıtları — ISSN Eşleşmesi
ILC3 deficiency and generalized ILC abnormalities in DOCK8‐deficient patients
2019 ISSN: 0105-4538 SCI
Prof. Dr. HASİBE ARTAÇ →
Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU
2019 ISSN: 0105-4538 SCI
Doç. Dr. KEMAL EROL →
Management of patients with chronic rhinosinusitis during the COVID\u201019 pandemic\u2014An EAACI position paper
2021 ISSN: 0105-4538 SSCI Q1
Prof. Dr. BANU BOZKURT →
Development and preclinical evaluation of virus\u2010like particle vaccine against COVID\u201019 infection
2021 ISSN: 0105-4538 SCI-Expanded
Prof. Dr. OSMAN ERGANİŞ →
Adverse COVID-19 outcomes in immune deficiencies: Inequality exists between subclasses
2022 ISSN: 0105-4538 SCI
Prof. Dr. HASİBE ARTAÇ →
Makale Bilgileri
ISSN01054538
Yayın TarihiOcak 2022
Cilt / Sayfa77 · 282-295
Scopus ID2-s2.0-85112115546
Özet
Background: Genetic deficiencies of immune system, referred to as inborn errors of immunity (IEI), serve as a valuable model to study human immune responses. In a multicenter prospective cohort, we evaluated the outcome of SARS-CoV-2 infection among IEI subjects and analyzed genetic and immune characteristics that determine adverse COVID-19 outcomes. Methods: We studied 34 IEI patients (19M/15F, 12 [min: 0.6-max: 43] years) from six centers. We diagnosed COVID-19 infection by finding a positive SARS-CoV-2 PCR test (n = 25) and/or a lung tomography scoring (CORADS) ≥4 (n = 9). We recorded clinical and laboratory findings prospectively, fitted survival curves, and calculated fatality rates for the entire group and each IEI subclass. Results: Nineteen patients had combined immune deficiency (CID), six with predominantly antibody deficiency (PAD), six immune dysregulation (ID), two innate immune defects, and one in the autoinflammatory class. Overall, 23.5% of cases died, with disproportionate fatality rates among different IEI categories. PAD group had a relatively favorable outcome at any age, but CIDs and IDs were particularly vulnerable. At admission, presence of dyspnea was an independent risk for COVID-related death (OR: 2.630, 95% CI; 1.198–5.776, p <.001). Concerning predictive roles of laboratory markers at admission, deceased subjects compared to survived had significantly higher CRP, procalcitonin, Troponin-T, ferritin, and total-lung-score (p =.020, p =.003, p =.014, p =.013, p =.020; respectively), and lower absolute lymphocyte count, albumin, and trough IgG (p =.012, p =.022, p =.011; respectively). Conclusion: Our data disclose a highly vulnerable IEI subgroup particularly disadvantaged for COVID-19 despite their youth. Future studies should address this vulnerability and consider giving priority to these subjects in SARS-Cov-2 therapy trials.
Yazarlar (21)
1
Elif Karakoc Aydiner
ORCID: 0000-0003-4150-5200
2
Sevgi Bilgic Eltan
ORCID: 0000-0003-0561-3343
3
Royale Babayeva
ORCID: 0000-0002-1044-2174
4
Omer Aydiner
ORCID: 0000-0003-4895-093X
5
Eda Kepenekli
ORCID: 0000-0003-1886-5224
6
Burcu Kolukisa
ORCID: 0000-0002-2399-8630
7
Asena Pinar Sefer
ORCID: 0000-0003-2667-0291
8
Ezgi Yalcin Gungoren
ORCID: 0000-0003-0958-7824
9
Esra Karabiber
ORCID: 0000-0002-8377-7637
10
Esra Ozek Yucel
ORCID: 0000-0003-3712-2522
11
Oner Ozdemir
ORCID: 0000-0002-5338-9561
12
Ayca Kiykim
ORCID: 0000-0001-5821-3963
13
Hasibe Artac
14
Nalan Yakici
ORCID: 0000-0003-0738-4679
15
Koray Yalcin
ORCID: 0000-0002-7638-9564
16
Haluk Cokugras
ORCID: 0000-0002-0086-3936
17
Tulin Tiraje Celkan
ORCID: 0000-0001-7287-1276
18
Fazil Orhan
19
Mehmet Akif Yesilipek
ORCID: 0000-0002-4514-8637
20
Safa Baris
ORCID: 0000-0002-4730-9422
21
Ahmet Ozen
Kurumlar
Division of Pediatric Hematology and Oncology
Istanbul Türkiye
Istanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies
Istanbul Turkey
İstanbul Tıp Fakültesi
Istanbul Turkey
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty of Medicine
Istanbul Turkey
Karadeniz Teknik Üniversitesi Tip Fakültesi
Trabzon Turkey
Kartal Training and Research Hospital
Istanbul Turkey
Marmara Üniversitesi
Istanbul Turkey
Marmara Üniversitesi Tip Fakültesi
Istanbul Turkey
Medical Park Göztepe Hospital
Istanbul Turkey
Sakarya Üniversitesi
Serdivan Turkey
Selçuk Tip Fakültesi
Konya Turkey
The Isil Berat Barlan Center for Translational Medicine
Istanbul Turkey
Scimago Dergi (ISSN Eşleşmesi)
Allergy: European Journal of Allergy and Clinical Immunology
Q1
SJR Skoru3,851
H-Index226
YayıncıWiley-Blackwell Publishing Ltd
ÜlkeUnited Kingdom
Immunology (Q1)
Immunology and Allergy (Q1)
Metrikler
39
Atıf
21
Yazar